TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03971409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given IV
Study: NCT04392882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legume enriched diet group
Description: * Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day
Study: NCT03478982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Alprazolam
Description: single dose for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Alprazolam
Description: single dose for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: single dose for inhalation
Study: NCT01700218

Intervention type: OTHER
Group type: OTHER
Intervention: telemonitoring

Intervention type: OTHER
Group type: OTHER
Intervention: control
Study: NCT02064491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT01647802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing attempts with the Vertic'Easy Device
Description: Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
Study: NCT02064491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study: NCT04136041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
Study: NCT04022473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bafiertam
Description: Over-encapsulated capsule to mask treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecfidera
Description: Over-encapsulated capsule to mask treatment
Study: NCT02869204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucocyte - Platelet rich Plasma
Description: Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
Study: NCT01592526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin + Nicotine
Description: Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin + Nicotine
Description: Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin + Nicotine
Description: Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotoxin + Nicotine
Description: Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
Study: NCT04551326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual hamstring stretching
Description: Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
Study: NCT00683670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mature dendritic cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mature dendritic cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mature dendritic cell vaccine
Study: NCT04334356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Web App
Description: App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
Study: NCT00483717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal (IN) placebo
Study: NCT05023499

Intervention type: DRUG
Intervention: SYMPT-X Glutamine, Oral Powder for Reconstitution
Description: erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.

Intervention type: DRUG
Intervention: SYMPT-X Glutamine, Oral Powder for Reconstitution
Description: erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
Study: NCT04303741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
Study: NCT03373656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine

Intervention type: OTHER
Group type: OTHER
Intervention: No Vaccination
Description: Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
Study: NCT03873662

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
Study: NCT03228615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDM Intervention
Description: Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
Study: NCT00938015

Intervention type: OTHER
Intervention: Questionnaire
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: Questionnaire
Description: This is a non-interventional study
Study: NCT03029754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive leg raise
Description: A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
Study: NCT03359278

Intervention type: PROCEDURE
Intervention: open reduction and internal fixation
Description: The volar approach was used for open reduction and internal fixation of distal radius fractures
Study: NCT05324839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: injecting different dosage to different group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: injecting different dosage to different group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: injecting different dosage to different group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: injecting different dosage to different group
Study: NCT00727675

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrated Cognitive Behavioral Therapy
Description: CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
Study: NCT03506334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVBT using Dynesys System Components
Description: Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine fusion
Description: Children with scoliosis undergoing fusion surgery will form the control arm
Study: NCT04180956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bias-reduction Intervention
Description: A training for doctors
Study: NCT02934126

Intervention type: OTHER
Intervention: breast cancer patients
Description: semi structured face to face interviews
Study: NCT03503565

Intervention type: PROCEDURE
Intervention: intraoperative neuromuscular blockade
Description: The intensity of intraoperative neuromuscular blockade

Intervention type: PROCEDURE
Intervention: intraoperative neuromuscular blockade
Description: The intensity of intraoperative neuromuscular blockade
Study: NCT04358809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of heat killed (autoclaved) Mycobacterium w
Description: Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo along with Standard of care (SOC) treatment for COVID-19
Study: NCT03024294

Intervention type: OTHER
Group type: OTHER
Intervention: Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy
Description: To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
Study: NCT04088227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Patients will receive platelet rich plasma injection two times prior to surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
Study: NCT01725100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212B (Standard DMSO content)
Description: Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212B (Lower DMSO content)
Description: Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
Study: NCT02163759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study: NCT03626337

Intervention type: DRUG
Intervention: Thiamine 100 MG/ML
Description: 100 mg thiamine provided as intramuscular injection
Study: NCT00845559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
Study: NCT02910895

Intervention type: OTHER
Group type: OTHER
Intervention: tumor biopsy
Description: biopsy
Study: NCT06690086

Intervention type: PROCEDURE
Intervention: Lesion biopsy
Description: Lesions enrolled in the study are biopsied to confirm histopathology

Intervention type: DEVICE
Intervention: DermaSensor Device Use
Description: Users are blinded to the DermaSensor Device result
Study: NCT00308854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic Therapy
Study: NCT01365364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Physical Exercise
Description: All individuals were submitted to physical exercise reaching maximum effort

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Physical Exercise
Description: All individuals were submitted to physical exercise reaching maximum effort

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Physical Exercise
Description: All individuals were submitted to physical exercise reaching maximum effort
Study: NCT00673777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT00348673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061
Description: Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453,061
Description: Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
Study: NCT01663012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Study: NCT04505332

Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthroplasty
Description: back pain in orthopedists due to working actively and performing arthroplasty every day
Study: NCT02012660

Intervention type: OTHER
Intervention: Seasonality
Description: The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
Study: NCT01284023

Intervention type: OTHER
Intervention: Shaving
Description: Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
Study: NCT02907684

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Muffins/Crackers
Description: Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation.
Study: NCT04177979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Near-assisted learning through trained peers
Description: Students randomly allocated to this group were overseen during sessions by trained peer instructors.
Study: NCT00946790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
Study: NCT01594619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Oral 25mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Oral 25mg tablet
Study: NCT03170544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
Study: NCT04960371

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary flow reserve (CFR)
Description: Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary flow reserve (CFR)
Description: Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.
Study: NCT03843060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
Study: NCT00879255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy Group Videoteleconference
Description: Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.